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ABSTRACT 
 
 Cancer-associated cachexia is characterized, among other symptoms, by a dramatic loss of 
both muscle and fat. In addition, the cachectic syndrome is often associated with anaemia. For this 
reason the object of the present investigation was to assess the effects of erythropoietin (EPO) 
treatment on experimental cancer-cachexia models. The results clearly show that, in addition to the 
improvement of the haematocrit, EPO treatment promoted a partial preservation of adipose tissue, 
while exerted negligible effects on muscle loss. The action of EPO reported here refers to both in 
vivo and in vitro studies. As for the former, administration of EPO to tumour-bearing animals 
resulted in a significant increase of lipoprotein lipase (LPL) activity in adipose tissue, suggesting 
that the treatment favoured triacylglycerol (TG) accumulation in the adipose tissue. The in vitro 
experiments, using both adipose tissue slices and 3T3-L1 adipocytes, suggest that EPO is able to 
increase the lipogenic rate through the activation of its specific receptor (EPOR) therefore 
suggesting that this metabolic pathway, in addition to TG uptake by LPL, may also contribute to the 
beneficial effects of EPO on fat preservation in cancer cachexia 
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INTRODUCTION 
 Cancer patients frequently develop a condition of general wasting known as cachexia. This 
is a multifactorial syndrome that complicates patients’ management, increases morbidity and 
mortality rates, reduces the tolerance to antineoplastic therapies, and results in poor quality of 
life(1). Cachexia is characterized by wasting of muscle and adipose tissue, anaemia, anorexia and 
perturbations of the hormonal homeostasis. It occurs in 54 to 70% of newly diagnosed cancer 
patients(2), worsening their prognosis and clinical management and accounting for about 25% of 
cancer deaths(3). The pathogenetic mechanisms underlying cachexia are complex and only 
partially identified, thereby effective therapeutic strategies are lacking.  
Anaemia is a frequent feature of patients with cancer cachexia, contributing to weight loss, 
reduced exercise capacity, and altered energy homeostasis(4). The incidence of anaemia varies 
with tumour type and stage, and patient’s age: up to one-third of cancer hosts are anaemic at 
diagnosis(5) and chemotherapy frequently increases this number. Cancer-associated anaemia can 
thus be considered a negative prognostic factor for survival(6). Anaemia can lead to hypoxia in 
several tissues, increasing lactate production and thereby promoting a decrease in intracellular pH 
that enhances muscle protein degradation, possibly exacerbating tissue wasting(7) Nevertheless, 
mechanistic data explaining how anaemia may contribute to the onset and progression of cachexia 
are still lacking. 
 Erythropoietin (EPO), a 34kDa glycoprotein, is synthesized by the kidney in response to 
hypoxemia. Its main function is to stimulate erythropoiesis by activating the EPO receptor (EPOR) 
on erythroid progenitor cells. EPO signals through phosphatidylinositol-3-kinase (PI3K)/Akt, signal 
transducer and activator of transcription 5 (STAT5), mitogen-activated protein kinase (MAPK) and 
protein kinase C pathways, inducing erythroblast production with a consequent rise in red blood 
cell count evident 1–2 weeks after EPO administration(8). EPO has been used for the treatment of 
cancer wasting to fight the anaemia associated with the cachectic syndrome. EPO treatment in 
unselected randomized cachectic cancer patients prevented the appearance of anaemia and the 
loss of exercise capacity, showing a trend to significant improvement in general health(9). It has 
also been used in combination with cyclooxygenase (COX) inhibitors(10). Moreover, in anaemic 
cancer patients with non-myeloid malignancies, EPO treatment increased haemoglobin levels, 
decreased transfusion requirements, and improved both patients’ functional status and quality of 
life(11). 
Recently, the discovery that EPOR is expressed on skeletal myoblasts suggests that the 
role of EPO may extend beyond erythropoiesis. Such hypothesis is supported by observations 
showing that EPO enhances the proliferation and reduces the differentiation of both primary 
satellite cell cultures and C2C12 myoblasts(12). Moreover, intra-muscular EPO administration after 
crush injury of rat skeletal muscle induces a faster and better regeneration with improved 
microcirculation(13). Besides the skeletal muscle, also the adipose tissue, that is strongly affected 
during cachexia, has been recently suggested as target of EPO action(14). Indeed, EPO 
administration to nude mice previously transplanted with human fat tissue determined longer 
survival and stimulated the angiogenesis of the grafts, such effects being comparable to those 
exerted by the pro-angiogenic protein vascular endothelial growth factor (VEGF)(14). 
 Considering the possible contribution of EPO signalling in the maintenance of both muscle 
and adipose tissue homeostasis, the aim of the present investigation was to examine, beyond the 
correction of anaemia, the effects of EPO treatment on either skeletal muscle or adipose tissue 
during experimental cancer cachexia. 
MATERIALS AND METHODS 
Experimental tumour models 
C57BL/6 and Balb/C mice weighing about 20 g (Interfauna, Barcelona, Spain) and Wistar 
rats weighing about 150 g (Interfauna, Barcelona, Spain) were maintained on a regular dark-light 
cycle (light from 08:00 to 20:00), with free access to food and water during the whole experimental 
period. They were cared for in compliance with the Policy on Humane Care and Use of Laboratory 
Animals (ILAR 2011). The Bioethical Committee of the University of Barcelona approved the 
experimental protocol. All animal manipulations were made in accordance with the European 
Community guidelines for the use of laboratory animals. The day of sacrifice, the animals were 
weighed and anaesthetized with an i.p. injection of ketamine/xylazine mixture (3:1) (Imalgene and 
Rompun respectively). Tissues were rapidly excised, weighed, and frozen in liquid nitrogen. 
A. Colon26 carcinoma 
Tumour-bearing mice were inoculated subcutaneously in the back with 5x105 Colon26 
carcinoma cells. Colon26 cells were maintained in vitro in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Invitrogen) supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 
µg/ml sodium pyruvate, 2 mM L-glutamine, at 37°C in a humidified atmosphere of 5% CO2 in air. 
The day of tumour implantation the cells were trypsinized, re-suspended in sterile saline and 
subsequently implanted in the back of the animals at the concentration indicated above. Animals 
were randomized and divided into two groups, namely controls (C) and tumour bearers (C26). C26 
where divided into two sub-groups: untreated and treated i.p. every three days with recombinant 
human EPO (100 IU, Calbiochem) adopting the same protocol of a previous work(14). Mice were 
sacrificed under anaesthesia 14 days after tumour implantation. 
 B. Lewis lung carcinoma 
  Mice received an intramuscular (hind leg) inoculum of 5x105 Lewis lung carcinoma cells 
obtained from previous tumour hosts. The Lewis lung carcinoma is a cachexia-inducing, rapidly 
growing murine tumour composed by poorly differentiated cells, with a relatively short doubling 
time(15). Animals were randomized and divided into two groups, namely controls (C) and tumour 
bearers (LLC). LLC where divided into two sub-groups: untreated and treated with EPO (100 IU) 
that was administered i.p. every three days. Mice were sacrificed under anaesthesia 14 days after 
tumour implantation.  
 C. AH-130 Yoshida ascites hepatoma 
 Male rats received an intraperitoneal inoculum of 10
8
 AH-130 Yoshida ascites hepatoma 
cells obtained from exponential tumours(16). On day 7 after tumour transplantation, the animals 
were sacrificed and the dorsal fat pads were excised for subsequent ex vivo experiments. 
Haematocrit  
 Total blood was withdrawn from anaesthetized mice by cardiac puncture and collected in 
heparinized tubes. A drop was used to fill haematocrit capillary tubes that were centrifuged in a 
haematocrit centrifuge for 5 min at 800 x g. Haematocrit was calculated as percentage of packed 
cell volume of the total blood. 
Lipoprotein lipase activity  
White adipose tissue (WAT) samples were homogenized in a buffer containing 10mM 
Hepes, 1mM EDTA, 1mM DTT, 250mM Sucrose, 5U/ml Heparin, pH 7.5 and used in an assay 
system containing [3H]triolein as substrate (17); [3H]fatty acids released after a 30 min incubation 
period were extracted and quantified by the method of Nilsson-Ehle and Schotz (18). 
EX vivo lipogenic rate 
After dissection, WAT from control and AH-130 bearing rats was weighed and sliced into 
fragments of about 15-20 mg. 100 mg (4-5 pieces) were incubated in 4 ml Krebs-Henseleit buffer 
(pH 7.4) containing 2% fatty acid-free bovine serum albumin, 5 mM D-glucose and 0,1 µCi/ml [1-
14C] acetate. Where indicated, the following substances were added: TNF (5 ng/ml), EPO 
(10U/ml) and insulin (4 µg/ml). Tissue slices were incubated for 1 hour at 37ºC in a shaking water 
bath under O2/CO2 (19:1) flow. Lipogenic rate was calculated by measuring [1-14C] acetate 
incorporation into fatty acids in WAT pieces as previously described(19). 
Ex vivo lipolytic rate 
The lipolytic rate was determined as previously described by López-Soriano et al. (20). 
After dissection, WAT from control and AH-130 bearing rats was weighed and sliced into pieces of 
about 15-20 mg. 100 mg (4-5 pieces) were incubated in 4 ml Krebs-Henseleit buffer (pH 7.4) 
containing 2% fatty acid-free bovine serum albumin and 5 mM D-glucose. Where indicated, the 
following substances were added: TNF (5 ng/ml), EPO (10U/ml), insulin (4 µg/ml) and 
isoproterenol (0.5 µM). Tissue slices were incubated for 1 hour at 37ºC in a shaking water bath 
under O2/CO2 (19:1) flow. Incubations were stopped by adding perchloric acid (final concentration 
3%). Lipolytic rate was estimated as the glycerol released to the incubation medium measured by 
the method of Hohorst et al.(21). 
Cell Culture and Adipocyte Differentiation 
 3T3-L1 preadipocytes (ATCC) were grown in DMEM supplemented with 10% (v/v) foetal 
calf serum (Invitrogen), 25 mM HEPES pH 7.0, 1,000 U/ml penicillin, 1,000 U/ml streptomycin, and 
25 µg/ml fungizone (BioWhittaker). To induce adipocyte differentiation, cells were grown for 2 days 
post confluence and then cultured in differentiation medium consisting of DMEM supplemented 
with 10% (v/v) foetal bovine serum (Invitrogen), 25 mM HEPES pH 7.0, 1,000 U/ml penicillin, 1,000 
U/ml streptomycin, and 25 µg/ml fungizone, plus MDI (0.5 mM isobutylmethyl-xanthine, 1µM 
dexamethasone and 1 µg/ml insulin). After 48 h, MDI was replaced with insulin (1 µg/ml) and the 
medium changed every two days. 
 
Immunofluorescence 
3T3-L1 monolayers at day 4 of differentiation were washed with PBS and fixed in acetone-
methanol (1:1), rehydrated with PBS containing 0.1% Triton X-100 and probed with an anti-EPOR 
primary antibody (R&D Systems, Minneapolis, MN, USA). Detection was performed using a Cy3-
conjugated goat IgG secondary antibody. Nuclei were stained with the Hoechst 33342 
fluorochrome and the images captured in an epiilluminated fluorescence microscope (Leica, 
Solms, Germany). 
Oil Red O staining 
Lipid accumulation in differentiating (Day 4) 3T3-L1 cells was assessed by Oil Red O 
staining. Briefly, cells were fixed for 15’ in 3% paraformaldehyde, rinsed three times in PBS and 
stained for 30’ with the lipophilic dye Oil Red O (Sigma) dissolved in 65% isopropanol. Dye excess 
was washed away and the cells were dried completely. Lipids were extracted with an 
exan/isopropanol mixture (3:2) and the absorbance read at 490nm. 
Cell growth curve 
 3T3-L1preadipocytes were seeded in 12-wells plates at 4*103 cells/sq cm in growth medium 
(see above). After 12 h (point zero) and every 24h (for 4 days) the cells were washed with PBS, 
fixed in 4% paraformaldehyde, stained with Crystal violet (0,1% in PBS), washed three times and 
dried completely. The dye was extracted with 10% acetic acid and the absorbance read at 590nm. 
Western blotting 
Total proteins from WAT samples or 3T3-L1 monolayers were extracted in RIPA buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM PMSF) with freshly 
added protease and phosphatase inhibitor cocktails, sonicated and centrifuged at 3000 x g for 5 
min at 4°C, and the supernatant collected. Protein concentration was assayed by the method of 
Lowry (22)  using BSA as working standard. Equal amounts of protein (30 µg) were heat-
denatured in sample-loading buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol), resolved by SDS-PAGE and transferred to nitrocellulose 
membranes. The filters were blocked with Tris-buffered saline (TBS) containing 0.05% Tween and 
5% non-fat dry milk and then incubated overnight with antibodies directed against: EPOR (R&D 
systems, Minneapolis, MN, USA), phosphorylated Akt (Cell Signalling, Beverly, MA, USA), total Akt 
(SantaCruz Biotechnology, Santa Cruz, CA, USA). Peroxidase-conjugated IgG (Bio-Rad, Hercules, 
CA, USA) were used as secondary antibodies. Membrane-bound immune complexes were 
detected by an enhanced chemiluminescence system (SantaCruz Biotechnology) on a photon-
sensitive film. Protein loading was normalized according to GAPDH (SantaCruz Biotechnology) 
expression. Band quantification was performed by densitometric analysis using a specific software 
(TotalLab, NonLinear Dynamics, Newcastle upon Tyne, UK). 
Real time-PCR 
Total RNA was obtained using the TriPure reagent (Roche) following manufacturer’s 
instructions. RNA concentration was determined fluorometrically using the Ribogreen reagent 
(Invitrogen). Total mRNA was retro-transcribed using the i-Script cDNA synthesis kit (Bio-Rad). 
Transcript levels were determined by using the SsoFast Evagreen Supermix and the MiniOpticon 
thermal cycler (Bio-Rad), normalizing the expression for both actin and calnexin levels. Primer 
sequences were as follows: PPARγ CGGAAGCCCTTTGGTGACTT 
TGGGCTTCACGTTCAGCAAG, aP2 CAGAAGTGGGATGGAAAGTCG 
CGACTGACTATTGTAGTGTTTGA, SREBP-1c GATGTGCGAACTGGACACAG 
CATAGGGGGCGTCAAACAG, FASN TCCACCTTTAAGTTGCCCTG 
TCTGCTCTCGTCATGTCACC, LPL TCTGTACGGCACAGTGG CCTCTCGATGACGAAGC, actin 
CTGGCTCCTAGCACCATGAAGAT GGTGGACAGTGAGGCCAGGAT, calnexin 
GCAGCGACCTATGATTGACAACC GCTCCAAACCAATAGCACTGAAAGG. 
Statistical Analysis 
 Data were analyzed by ANOVA. Statistical significance of results is indicated by: *p < 0.05, 
**p < 0.01, ***p < 0.001. 
RESULTS AND DISCUSSION 
Cambiare numerazione figure, discutere protezione della metabolic capacity (Lundholm 1998, 
Daneryd 2002)! 
In order to study the effects of EPO on tumour-induced wasting, we used two different 
murine experimental models: the Colon26 carcinoma (C26) and the Lewis lung carcinoma (LLC). 
As expected, tumour growth in both animal models resulted in important changes in body weight 
(Table 1; C26 -22%; LLC -22%) as well as in muscle (C26: GSN -23%, Tibialis -25%; LLC: GSN -
29%, Tibialis -32%) and white adipose tissue (WAT) mass (C26: dorsal WAT -85%, epididimal 
WAT -77%; LLC: dorsal WAT -95%, epididimal WAT -87%). In both models, tumour-bearing mice 
showed reduced haematocrit; such effect was more evident in the LLC (-56%) than in the C26 
hosts (-16%). EPO treatment did not modify either body or muscle weights in any of the groups. By 
contrast, in the C26-bearing animals EPO administration significantly increased both dorsal and 
epididimal WAT (+108% and +73%, respectively; Table 1A) as compared to the untreated tumour-
bearing mice. Similar, but quantitatively more marked, results were found in the LLC-bearing mice 
(dorsal WAT: +200%, epididimal WAT: +112%; Table 1B). Finally, EPO treatment resulted in 
significant haematocrit rescue in both tumour-bearing groups (C26 +12%; LLC +20%), in the latter 
case not sufficient to re-establish the control levels. Food intake non cambia, quindi la protezione 
non dipende da maggiore calorie intake, mentre non siamo in grado di stabilire eventuali differenze 
di energy expenditure. 
 The results obtained in the LLC-bearing mice administered EPO, i.e. a relevant rescue of 
adipose tissue loss despite a small and far from complete rescue of anaemia prompted us to 
investigate the specific action of EPO in this tissue. The first step in order to define a direct rather 
than indirect action of the cytokine in the WAT was to assess the presence of the specific EPO 
receptor in the tissue. The results presented in Figure 1 clearly show that the receptor is expressed 
in the adipose tissue of both control and tumour-bearing mice at similar levels; moreover, EPO 
administration stimulated EPOR accumulation (+84%) in LLC-bearing mice. Such data are in 
agreement with the protective effects (Table 1) reported on WAT and point to a direct role of EPO 
regulated signalling in the control of adipose tissue mass. Such a hypothesis is consistent with 
recent observations that reported the functional expression of EPOR in human adipose tissue(14). 
EPO effects are mediated by EPOR that transmits the intracellular signal mainly through the JAK-
STATS or the PI3K-Akt pathways. Since the latter signalling pathway regulates adipocyte growth 
and anabolism, we measured the levels of total and phosphorylated Akt, a serine-threonine kinase 
downstream of PI3K. The results presented in Figure 2 show that the implantation of LLC led to a 
decrease of phosphorylated Akt, in agreement with decreased anabolic processes in the WAT of 
tumour-bearing animals. Treatment with EPO was able to partially prevent such a reduction, 
suggesting that the protective effects of EPO on adipose tissue against cancer cachexia are 
partially mediated through this intracellular signalling pathway (Figure 2).  
To clarify the mechanisms underlying EPO-induced improvement of WAT depletion in 
tumour-bearing animals, the different pathways associated with fat accumulation have been 
investigated. Fatty acids (FA) enter adipose tissue through the action of lipoprotein lipase (LPL) on 
either VLDL (endogenous triacylglycerol) or chylomicra (exogenous triacylglycerol). This enzyme, 
located in the endothelial cells, breaks down triacylglycerol (TAG) into FA and glycerol. The FA can 
then be esterified and incorporated into tissue TAG. Total LPL activity is markedly reduced in mice 
bearing the LLC tumour (Figure 3). This observation is in agreement with previous results from our 
laboratory(23). Treatment with EPO significantly increases total LPL activity in tumour-bearing 
mice, although it still remains lower than control values. These data agree with the results obtained 
by Goto and co-workers in haemodialysis patients(24).  
In addition to the entry of FA into adipose tissue through LPL, FA can also be synthesized 
de novo through lipogenesis inside the adipose tissue. For this reason, the effects of EPO on the 
lipogenic rate were investigated by measuring the incorporation into lipids of [1-14C]-acetate in rat 
WAT slices incubated in the presence of different stimuli. Figure 4A shows the rates of lipogenesis 
in different conditions. As expected, the lipogenic rate is markedly induced by insulin and 
significantly reduced by incubation of WAT slices with tumour necrosis factor alpha (TNF). 
Interestingly, while EPO alone had no significant lipogenic effects, it is able to abrogate TNF 
effects. In the attempt to compare experimental cachexia with direct TNF effects on lipogenesis, a 
rat cachexia model (AH-130 Yoshida ascites hepatoma) was used. As expected, the lipogenic rate 
in WAT slices from tumour-bearing rats was markedly reduced. Of interest, such reduction was 
significantly improved (+130%) by the addition of EPO in the incubation medium. These results 
suggest that, in addition to LPL, lipogenesis also contributes to fat accretion observed as a result of 
EPO treatment in cachectic tumour-bearing animals.  
Finally, the effects of EPO on adipose tissue could rely on decreased lipolyitic rate. In order 
to test this hypothesis, we measured the glycerol release in WAT slices from control and AH-130-
bearing rats in the presence of EPO. The results presented in Figure 4B show that both 
isoproterenol and TNF increased the rate of glycerol release (+34% and +274%, respectively), 
while insulin, as expected, exerted an opposite effect (-43%). Unexpectedly, the glycerol release 
from AH-130 samples was lower than the respective controls, such effect likely depending on the 
smaller amount of lipids present in the tissue of the former ones. No effects of EPO were observed 
on lipolysis in WAT from either control or tumour-bearing animals and from both TNF and 
isoproterenol treated samples, therefore excluding any EPO action on the regulation of lipolysis. 
 The effects exerted by EPO on the adipose tissue have been further investigated at the 
molecular level taking advantage of an in vitro model system, namely the 3T3-L1 pre-adipocytes, 
that can be induced to adipocyte differentiation when cultured in appropriate conditions (see 
Materials and methods). As shown in Figure 5, EPO administration to differentiating cells resulted 
in increased accumulation of lipid droplets as observed by both morphological appearance and 
quantification of Oil red O uptake. Such effect is associated with increased EPOR staining. In 
agreement with the above reported ex vivo results using WAT slices (Figure 4), the addition of TNF 
to the culture medium decreased lipid accumulation, an effect that was prevented by EPO. PCR 
che conferma in vitro I dati ottenuti in.vivo dimostrando che EPO è in grado di attivare direttemente 
l’adipogenesi e di contrastare, almeno in parte, l’inibizione imposta dal TNF. The EPOR expression 
was then evaluated in a time-course experiment, from growing to fully differentiated cells. Figure 6A 
shows that the presence of EPO increased the receptor expression in growing cells and prolonged 
the expression during the early phases of differentiation while then rapidly disappeared. These data 
suggest that EPO exerts its effects on the adipose tissue mainly targeting proliferating and 
differentiating pre-adipocytes though not fully differentiated adipocytes. On this line, a growth curve 
of pre-adipocytes was performed in order to clarify if EPO action might rely on adipocyte 
hyperplasia rather than hypertrophy. The results showed that EPO administration did not affect the 
cell proliferation rate (Figure 6B), clarifying that EPO is mainly responsible for the induction of 
lipogenesis and doesn’t impinge on cell growth. 
 The results shown in the present study are consistent with a beneficial effect of EPO 
treatment on the preservation of adipose tissue wasting associated with cancer. Indeed, fat loss 
during cancer is a common trend both in humans and experimental models (25). As a 
consequence, some authors indicated that fat loss is associated with both poor prognosis and 
reduced survival during cancer (26). By contrast, no effects of EPO were observed in the 
preservation of skeletal muscle mass. These results are in contrast with a recent publication 
suggesting that preservation of adipose tissue during cachexia resulted in preservation of muscle 
mass, as if the muscle wasting was directly associated with the loss of adipose tissue(27). 
Concerning the metabolic pathways involved in the actions of EPO on fat mass, the results 
presented here clearly suggested that the cytokine acts on both lipogenesis and LPL-mediated 
uptake of circulating TAG (Figure 7). 
 In conclusion, EPO administration to cancer patients might be useful to counteract anaemia, 
often present in cancer cachexia, but also to preserve adipose tissue homeostasis and fat stores. 
Moreover, in the last few years adipose tissue has been recognised as an "endocrine tissue”, due 
to the several cytokines and hormones released by adipocytes, thus highlighting the importance of 
its preservation in the design of future cancer cachexia treatments. Further studies are needed in 
order to better clarify the mechanisms of EPO action in non-hematopoietic cells. Furthermore, 
recent data showing that functional EPOR is absent in several human tumour cell lines(28) reduce 
the concerns regarding EPO safety for future clinical trials. 
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FIGURE LEGENDS 
FIGURE 1 
Representative patterns (lower) and densitometric analysis (upper) of EPOR (A) and  
phosphorylated (Ser473) and total Akt (B) expression measured in WAT protein extracts. C= 
control mice; LLC= Lewis lung carcinoma-bearing mice; EPO= erythropoietin administered. C. 
Lipoprotein lipase (LPL) enzymatic activity in WAT protein extracts. Data (means ± SD) are 
expressed as percentages of controls. Significance of the differences: * p<0.05 vs C; ** p<0.01 vs 
C; $ p<0.05 vs LLC. 
FIGURE 2 
A. Lipogenic rate assayed on WAT fragments measuring the incorporation into lipids of [1-14C] 
acetate (see methods). B. Lipolytic rate assayed on WAT fragments measuring the glycerol 
release (see methods). C= WAT from control rat; AH-130 = WAT from AH-130 bearing rat. Data 
(means ± SD) are expressed as percentages of controls. Significance of the differences: ** p<0.01 
vs C; *** p<0.001 vs C; $$ p<0.01 vs TNF; # p<0.05 vs AH-130. 
FIGURE 3 
A. Phase contrast microscopy (upper images) and EPO receptor immunofluorescence (lower 
images; blue: nuclei) of 3T3-L1 adipocytes at early (4 days) differentiation stages. B. Lipid 
accumulation measured as Oil Red O uptake. C. mRNA levels of genes related to adipogenesis. 
Data (means ± SD) are expressed as percentages of controls. Significance of the differences: * 
p<0.05 vs C; $ p<0.05 vs TNF. 
FIGURE 4 
A. Representative pattern of EPOR time-course expression during 3T3-L1 growth and 
differentiation. B. Growth curve in preadipocytes (Crystal violet staining, see Material and 
methods). 
FIGURE 5 
Schematic drawing of EPO actions on the adipose tissue. 
Table 1. Body and tissue weights of tumour-bearing mice. 
 
A. C26 tumour model 
 
 
  CONTROL (7) C26 (7) C26+EPO (6) 
IBW 
(g) 
25,30 ± 0,68  24,92 ± 0,55   24,52 ± 0,62   
FBW 
(g) 
26,98 ± 0,72  20,94 ± 0,86 *** 21,71 ± 0,85 ***  
Cumulative food intake 
(g) 
50,31 39,90 40,86 
Tumour  
(mg/100 g IBW) 
 1563 ± 200   1602 ± 173  
Haematocrit 
(%) 
51,02 ± 0,80  42,80 ± 0,69 *** 47,98 ± 1,12  §§ 
epididimal WAT  
(mg/100g IBW) 
608 ± 46  200 ± 30 **  346 ± 39 *§  
dorsal WAT  
(mg/100g IBW) 
407 ± 40  61 ± 15 ***  127 ± 22 *** §  
Gastrocnemius (mg/100g 
IBW) 
534 ± 13   409 ± 11 *** 439 ± 24  ** 
Tibialis 
(mg/100g IBW) 
181 ± 3   136 ± 5 *** 143 ± 11  ** 
  
  
B. LLC tumour model 
  CONTROL (6) LLC (7) LLC+EPO (7) 
IBW  
(g) 
19,23 ± 0,71   19,89 ± 0,19   19,98 ± 0,03  
FBW  
(g) 
20,84 ± 0,44   16,36 ± 0,50 ***   17,75 ± 0,25 ***§ 
Tumour   
(mg/100 g IBW) 
 5052 ± 150   4967 ± 375  
Cumulative food intake 
(g) 
44,27 38,12 37,85 
Haematocrit 
(%) 
59,09 ± 0,25   25,79 ± 0,55 ***  30,91 ± 0,59 ***§  
epididimal WAT  
(mg/100g IBW) 
1151 ± 62   145 ± 30 ***  307 ± 46 ***§  
dorsal WAT  
(mg/100g IBW) 
277 ± 34   14 ± 4 ***  42 ± 8 ***§§  
Gastrocnemius  
(mg/100g IBW) 
551 ± 16   390 ± 18 ***   417 ± 10 ***  
Tibialis 
 (mg/100g IBW) 
189 ± 9   128 ± 6 ***  124 ± 3 *** 
  
 
Results are mean ± S.E.M. for the number of animals indicated in parenthesis. Tissue weights are 
expressed as mg/100 g of initial body weight. Final body weight (FBW) excludes the tumour mass. 
IBW: Initial body weight, WAT: white adipose tissue. Statistical significances analysed using 
ANOVA.  
 
  
 
 
  
  
  
  
 
